CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Merdury Biopharmaceutical Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Merdury Biopharmaceutical Corp
15F
No.653, Bannan Road, Zhonghe District
Phone: +886 282212020p:+886 282212020 NEW TAIPEI, 235  Taiwan Ticker: 69326932
Business Summary
Merdury Biopharmaceutical Corp is a Taiwan-based company mainly engaged in the research, development and sale of pharmaceuticals. The Company mainly focuses on the development of drugs that do not meet special medical needs, difficult generic drugs and second-class new drugs. With the self-developed and multi-national patented drug development platform StackDose, the Company can develop products that can achieve controllable time-dissolving (instant or sustained release) tablets, thereby controlling the time for the drug to take effect. The main products include Sildenafil, Metformin, Tadalafil, Zolpidem, angina drugs, migraine drugs, multi-ingredient antihypertensive drugs and others. The products are mainly sold in Taiwan and the United States.
(Source: F-4)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023-----

Industries
SIC Code Description
2834 Pharmaceutical preparations
5122 Drugs, drug proprietaries, and druggists' sundries
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
General Manager, Director YaorenLiang 2/8/2023 2/8/2023
Deputy General Manager-Administration Division, Corporate Governance Officer ChunchunZhang 5/29/2024
Independent Director XinbeiShen 6/6/2024 6/6/2024

General Information
Number of Employees: 13 (As of 12/31/2022)
Outstanding Shares: 414,497,760 (As of 8/31/2024)
Shareholders: 5,077
Stock Exchange: TPO
Fax Number: +886 222215252


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024